Zobrazeno 1 - 10
of 117
pro vyhledávání: '"JL Revuelta"'
Autor:
D Gomez, C Serra, G Marina, V Escudero, Jl Revuelta, Y Rioja, G Oarbeascoa, A Herran, M Sanjurjo
Publikováno v:
Late breaking abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b271129cf7df4194f3c4577f6c886e46
https://doi.org/10.1136/ejhpharm-2023-eahp.438
https://doi.org/10.1136/ejhpharm-2023-eahp.438
Autor:
V. Escudero Vilaplana, I Taladriz Sender, J Vicente Valor, R Collado Borell, M Sanjurjo Sáez, JL Revuelta Herrero, C Villanueva Bueno, FJ Garcia Moreno, E González-Haba Peña
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Cancer patients are a vulnerable population for SAR-CoV-2 infection Aim and objectives The aim of our study was to describe the epidemiology and clinical course of patients with cancer infected with SARS-Cov-2, attending hos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cfdb082baaef1be94e8de704cda6686
https://doi.org/10.1136/ejhpharm-2021-eahpconf.114
https://doi.org/10.1136/ejhpharm-2021-eahpconf.114
Autor:
JL Revuelta Herrero, E González Haba-Peña, A De Lorenzo-Pinto, MN Sanchez-Fresneda, Raquel García-Sánchez, Vicente Escudero-Vilaplana, Ana Herranz-Alonso, Roberto Collado-Borrell, María Sanjurjo-Sáez, María Belén Marzal-Alfaro
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background To our knowledge, there is no pharmacy stratification model for patients in the oncology ambulatory setting. Purpose To develop a tool to stratify oncology patients that helps us to implement ambulatory clinical pharmacy services. Material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4af81707bcbe246fc7ae3af35e116ef5
https://doi.org/10.1136/ejhpharm-2019-eahpconf.276
https://doi.org/10.1136/ejhpharm-2019-eahpconf.276
Autor:
M Sanjurjo Sáez, S. Pernia Lopez, RM Romero Jiménez, A Melgarejo Ortuño, C Ortega Navarro, A Herranz Alonso, FJ Garcia Moreno, JL Revuelta Herrero
Publikováno v:
Eur J Hosp Pharm
Background Parenteral nutrition has been classified as a high-alert medication. In recent years, quality organisations such as the Joint Commission require hospitals to conduct proactive risk assessments of high-risk processes. Purpose To describe th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e24bf4e29aa7ca9d8b98abaee1c6b5c
https://europepmc.org/articles/PMC7535544/
https://europepmc.org/articles/PMC7535544/
Autor:
E García Martín, MS Pernía López, B Monje, PA Martínez Ortega, C Ortega Navarro, JL Revuelta, C Ruiz Martínez, A Herranz Alonso, M Sanjurjo Sáez
Publikováno v:
Production and preparation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5623deaf27e500144dfaf2011019141e
https://doi.org/10.1136/ejhpharm-2017-000640.473
https://doi.org/10.1136/ejhpharm-2017-000640.473
Autor:
María Sanjurjo-Sáez, Vicente Escudero-Vilaplana, Beatriz Monje, M Tovar-Pozo, JL Revuelta, C Ortega-Navarro, Xandra García-González
Publikováno v:
European Journal of Hospital Pharmacy. 23:A13.3-A14
Background In April 2009, lenalidomide was included in the hospital formulary for the treatment of multiple myeloma (MM) in patients who had received at least one previous therapy. The recommended starting dose (25 mg of lenalidomide) should be adjus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c5cb3396d0fd4d902e54afc858c8adb
https://doi.org/10.1136/ejhpharm-2016-000875.31
https://doi.org/10.1136/ejhpharm-2016-000875.31
Autor:
María Sanjurjo, M. N. Sánchez Fresneda, M Mañes Sevilla, C. Pérez Sanz, Eva González-Haba, JL Revuelta, Pernia, Ana Herranz, R Collado Borrell
Publikováno v:
European Journal of Hospital Pharmacy. 23:A80.1-A80
Background Mucositis is one of the most frequent complications in patients receiving chemotherapy. Currently there is no standard treatment, and its management is essentially based on adequate oral hygiene and mouthwashes. In our hospital, the pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::051bb9842ca6546e248811a42785ba4e
https://doi.org/10.1136/ejhpharm-2016-000875.181
https://doi.org/10.1136/ejhpharm-2016-000875.181
Autor:
C Ortega-Navarro, Vicente Escudero-Vilaplana, C Ruiz-Martínez, Beatriz Monje, JL Revuelta, María Sanjurjo-Sáez, Xandra García-González
Publikováno v:
European Journal of Hospital Pharmacy. 23:A127.2-A127
Background In 2009, lenalidomide was included in our hospital formulary for the treatment of multiple myeloma (MM). Presently, real world data are fundamental in the evaluation of drugs. Purpose To assess the effectiveness and safety of lenalidomide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5416aaeb6c861b1995fdfffe5bfb288
https://doi.org/10.1136/ejhpharm-2016-000875.289
https://doi.org/10.1136/ejhpharm-2016-000875.289
Autor:
B. Marzal Alfaro, Almudena Ribed, Ana Herranz-Alonso, A De Lorenzo-Pinto, JL Revuelta, C Ortega Navarro, M Tovar-Pozo, María Sanjurjo-Sáez, ML Martin-Barbero
Publikováno v:
European Journal of Hospital Pharmacy. 23:A141.1-A141
Background Mobility impairment is a major concern for patients with multiple sclerosis (MS). Dalfampridine improves walking speed. Nevertheless, it entails self-administration and there are few data on adherence rate, patient satisfaction and quality
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efc20bfb3b65cf8c1defd8a4f5eadcf1
https://doi.org/10.1136/ejhpharm-2016-000875.319
https://doi.org/10.1136/ejhpharm-2016-000875.319
Autor:
X García González, RM Romero Jiménez, M Tovar Pozo, C Ortega Navarro, C Ruiz Martinez, JL Revuelta, B Monje, M Sanjurjo Sáez, S Pernía
Publikováno v:
European Journal of Hospital Pharmacy. 23:A241.1-A241
Background According to the Institute of Medicine, inadequate medication labelling accounts for 33% of medication errors. As part of the institutional risk management strategy, in 2015 a multidisciplinary team redesigned the labels for hospital compo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4126070593837ad3542fc8f3585904d
https://doi.org/10.1136/ejhpharm-2016-000875.547
https://doi.org/10.1136/ejhpharm-2016-000875.547